CP-154,526

Names
Preferred IUPAC name

N-Butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[3,2-e]pyrimidin-4-amine

Identifiers

CAS Number

* 157286-86-7 Y

3D model (JSmol)

* Interactive image

ChEMBL |

* ChEMBL9946 N

ChemSpider |

* 4470592 N

IUPHAR/BPS

* 3495

PubChem CID

* 5311055

UNII |

* 9A549FB00R Y

CompTox Dashboard (EPA)

* DTXSID201027582

InChI

* InChI=1S/C23H32N4/c1-8-10-11-26(9-2)22-20-18(6)14-27(23(20)25-19(7)24-22)21-16(4)12-15(3)13-17(21)5/h12-14H,8-11H2,1-7H3 N

Key: FHQYJZCJRZHINA-UHFFFAOYSA-N N

* InChI=1/C23H32N4/c1-8-10-11-26(9-2)22-20-18(6)14-27(23(20)25-19(7)24-22)21-16(4)12-15(3)13-17(21)5/h12-14H,8-11H2,1-7H3

Key: FHQYJZCJRZHINA-UHFFFAOYAW

SMILES

* CCCCN(CC)C1=NC(=NC2=C1C(=CN2C3=C(C=C(C=C3C)C)C)C)C

Properties

Chemical formula

| C23H32N4
Molar mass | 364.52698

Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

N verify (what is YN ?)

Infobox references

Chemical compound

CP-154,526 is a potent and selective antagonist of the corticotropin releasing hormone receptor 1 developed by Pfizer.[1]

CP-154,526 is under investigation for the potential treatment of alcoholism.[2][3]

## See also

[edit]

* Antalarmin
* Pexacerfont
* Corticotropin releasing hormone antagonist

## References

[edit]

1. ^ Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD, Winston EN, Chen YL, Heym J (September 1996). "CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors". Proceedings of the National Academy of Sciences of the United States of America. 93 (19): 10477–82\. Bibcode:1996PNAS...9310477S. doi:10.1073/pnas.93.19.10477. PMC 38410. PMID 8816826.
2. ^ "Drug Has Potential To Prevent Alcoholics From Relapsing". Science News. ScienceDaily. 2008-08-02. Retrieved 2008-08-09.
3. ^ Pastor R, McKinnon CS, Scibelli AC, Burkhart-Kasch S, Reed C, Ryabinin AE, Coste SC, Stenzel-Poore MP, Phillips TJ (July 2008). "Corticotropin-releasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: a urocortin1-independent mechanism". Proceedings of the National Academy of Sciences of the United States of America. 105 (26): 9070–5\. Bibcode:2008PNAS..105.9070P. doi:10.1073/pnas.0710181105. PMC 2449366. PMID 18591672.

## Further reading

[edit]

* Seymour PA, Schmidt AW, Schulz DW (2006). "The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review". CNS Drug Reviews. 9 (1): 57–96\. doi:10.1111/j.1527-3458.2003.tb00244.x. PMC 6741649. PMID 12595912.
* Navarro-Zaragoza J, Núñez C, Laorden ML, Milanés MV (May 2010). "Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal". Molecular Pharmacology. 77 (5): 864–73\. doi:10.1124/mol.109.062463. PMID 20159948. S2CID 18588298.
* Kobayashi T, Kiyokawa Y, Takeuchi Y, Mori Y (September 2011). "Pretreatment with CP-154526 blocks the modifying effects of alarm pheromone on components of sexual behavior in male, but not in female, rats". Chemical Senses. 36 (7): 623–32\. doi:10.1093/chemse/bjr017. PMID 21502338.

## External links

[edit]

* CP+154526 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

* v
* t
* e

Antidepressants (N06A)

Specific reuptake inhibitors or receptor modulators

| SSRIsTooltip Selective serotonin reuptake inhibitors|

* Citalopram
* Escitalopram
* Fluoxetine#
* Fluvoxamine
* Indalpine‡
* Paroxetine
* Sertraline
* Zimelidine‡

|

SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors|

* Desvenlafaxine
* Duloxetine
* Levomilnacipran
* Milnacipran
* Tofenacin
* Venlafaxine

NRIsTooltip Norepinephrine reuptake inhibitors|

* Atomoxetine
* Reboxetine
* Viloxazine

NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors|

* Amineptine‡
* Bupropion
* Nomifensine‡

NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants|

* Mianserin
* Mirtazapine
* Setiptiline

SARIsTooltip Serotonin antagonist and reuptake inhibitors|

* Etoperidone
* Nefazodone
* Trazodone

SMSTooltip Serotonin modulator and stimulators|

* Vilazodone
* Vortioxetine

Others|

* Agomelatine
* Amisulpride
* Dextromethorphan/bupropion
* Esketamine
* Etryptamine‡
* Gepirone
* Indeloxazine
* Flupentixol
* Ketamine§
* Medifoxamine‡
* Metryptamine‡
* Oxaflozane‡
* Pivagabine‡
* Tandospirone
* Teniloxazine
* Tianeptine

Tricyclic and tetracyclic antidepressants

| TCAsTooltip Tricyclic antidepressants|

* Amineptine‡
* Amitriptyline#
* Amitriptylinoxide
* Amoxapine
* Butriptyline‡
* Clomipramine#
* Demexiptiline‡
* Desipramine
* Dibenzepin
* Dimetacrine‡
* Dosulepin
* Doxepin
* Imipramine
* Imipraminoxide‡
* Iprindole‡
* Lofepramine
* Melitracen
* Metapramine‡
* Nitroxazepine
* Nortriptyline
* Noxiptiline
* Opipramol
* Pipofezine
* Propizepine‡
* Protriptyline
* Quinupramine‡
* Tianeptine
* Trimipramine

|

TeCAsTooltip Tetracyclic antidepressants|

* Maprotiline
* Mianserin
* Mirtazapine
* Setiptiline

Others|

* Tiazesim

Monoamine oxidase inhibitors

| Non-selective|

* Irreversible: Benmoxin‡
* Iproclozide‡
* Iproniazid‡
* Isocarboxazid
* Isoniazid#
* Linezolid#
* Mebanazine‡
* Nialamide‡
* Octamoxin‡
* Phenelzine
* Pheniprazine‡
* Phenoxypropazine‡
* Pivhydrazine‡
* Safrazine‡
* Tedizolid
* Tranylcypromine

* Reversible: Caroxazone‡

* Mixed: Bifemelane

|

MAOATooltip Monoamine oxidase A-selective|

* Reversible: Eprobemide
* Metralindole
* Minaprine‡
* Moclobemide
* Pirlindole
* Tetrindole
* Toloxatone

MAOBTooltip Monoamine oxidase B-selective|

* Irreversible: Selegiline

Adjunctive therapies

* Atypical antipsychotics (aripiprazole, brexpiprazole, lurasidone, olanzapine, quetiapine, risperidone)
* Buspirone
* Lithium (lithium carbonate, lithium citrate)
* Thyroid hormones (triiodothyronine (T3), levothyroxine (T4))

Miscellaneous

* Ademetionine (SAMe)
* GABAkine neurosteroids (brexanolone, zuranolone)
* Hypericum perforatum (St. John's Wort)
* Oxitriptan (5-HTP)
* Rubidium chloride (RbCl)
* Tryptophan

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

* v
* t
* e

Anxiolytics (N05B)

5-HT1ARTooltip 5-HT1A receptor agonists|

* Buspirone
* Gepirone
* Tandospirone

GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators|

* Benzodiazepines: Adinazolam
* Alprazolam
* Bromazepam
* Camazepam
* Chlordiazepoxide
* Clobazam
* Clonazepam
* Clorazepate
* Clotiazepam
* Cloxazolam
* Diazepam#
* Ethyl loflazepate
* Etizolam
* Fludiazepam
* Halazepam
* Ketazolam
* Lorazepam#
* Medazepam
* Nordazepam
* Oxazepam
* Pinazepam
* Prazepam; Others: Alpidem‡
* Barbiturates (e.g., phenobarbital)
* Carbamates (e.g., meprobamate)
* Carisoprodol
* Chlormezanone‡
* Ethanol (alcohol)
* Etifoxine

Hypnotics|

* Zopiclone

Gabapentinoids
(α2δ VDCC blockers)|

* Gabapentin
* Gabapentin enacarbil
* Phenibut
* Pregabalin

Antidepressants|

* SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram)
* SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine)
* SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone)
* TCAsTooltip Tricyclic antidepressants (e.g., clomipramine#)
* TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine)
* MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine
* Bupropion
* Tianeptine
* Vilazodone
* Vortioxetine

Antipsychotics|

* Quetiapine
* Flupentixol

Sympatholytics
(Antiadrenergics)|

* Alpha-1 blockers (e.g., prazosin)
* Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine)
* Beta blockers (e.g., propranolol)

Others|

* Benzoctamine
* Cycloserine
* Fabomotizole
* Hydroxyzine
* Lorpiprazole
* Mebicar
* Mepiprazole
* Nicotine
* Opipramol
* Oxaflozane‡
* Phenaglycodol
* Phenibut
* Picamilon
* Selank
* Tiagabine
* Tofisopam
* Validolum

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[CID]: Compound ID
*[EPA]: U.S. Environmental Protection Agency
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template
*[SSRIs]: Selective serotonin reuptake inhibitors
*[SNRIs]: Serotonin-norepinephrine reuptake inhibitors
*[NRIs]: Norepinephrine reuptake inhibitors
*[NDRIs]: Norepinephrine–dopamine reuptake inhibitors
*[NaSSAs]: Noradrenergic and specific serotonergic antidepressants
*[SARIs]: Serotonin antagonist and reuptake inhibitors
*[SMS]: Serotonin modulator and stimulators
*[TCAs]: Tricyclic antidepressants
*[TeCAs]: Tetracyclic antidepressants
*[MAOA]: Monoamine oxidase A
*[MAOB]: Monoamine oxidase B
*[SAMe]: S-adenosyl-L-methionine
*[5-HTP]: 5-hydroxytryptophan
*[5-HT1AR]: 5-HT1A receptor
*[GABAAR]: GABAA receptor
*[PAMs]: positive allosteric modulators
*[α2δ]: alpha2delta subunit
*[VDCC]: voltage-dependent calcium channel
*[MAOIs]: Monoamine oxidase inhibitors